Gallant Lab · literature review · review paper
Creatine transporter deficiency and the two creatine synthesis defects, GAMT and AGAT deficiency, all empty the brain of creatine. Two of them can be treated with a dietary supplement, and the third has resisted every therapy tried so far. This review reads the 587-reference cerebral creatine deficiency corpus, 1886 to 2026, from the nineteenth-century creatinine assay to intranasal creatine prodrugs.
Abstract
The cerebral creatine deficiency syndromes are three inborn errors that share one deficit: too little creatine in the brain. GAMT and AGAT deficiency block the two steps of creatine synthesis, and creatine transporter deficiency (CTD), caused by variants in the X-linked gene SLC6A8, blocks creatine uptake into cells. All three cause intellectual disability, severe speech delay, epilepsy and behavioral problems. This review follows the field from its biochemical roots to the present, using a verified bibliography read through abstract-derived summaries. Creatine biochemistry had been worked out long before the disorders were found. They were found because in vivo proton magnetic resonance spectroscopy (MRS) can see the creatine peak, and in each disorder that peak was missing. GAMT deficiency was described in 1994 and the other two in 2001. Biochemical tests in urine and blood then allowed patient screening, and GAMT deficiency has now entered newborn screening. Treatment has diverged sharply. Oral creatine restores brain creatine in both synthesis defects, and children treated before symptoms appear can develop normally. In CTD, oral creatine cannot enter the brain, and precursor supplements help a minority at best. The current candidates are creatine analogs and prodrugs, pharmacological correctors of misfolded transporters, and gene therapy, none yet proven in patients. MRS remains the defining diagnostic sign and the main biomarker of whether a treatment reaches the brain.
Section 1
Creatine and phosphocreatine form an energy reserve in tissues whose demand for ATP rises and falls quickly, such as muscle and brain. Creatine is made in two steps. AGAT (L-arginine:glycine amidinotransferase, gene GATM) transfers the amidino group of arginine to glycine to make guanidinoacetate (GAA). GAMT (guanidinoacetate methyltransferase) then methylates GAA to creatine. Cells take creatine up through a sodium- and chloride-dependent transporter, SLC6A8. A defect at any of these three points lowers brain creatine.
The three disorders differ in what accumulates and in how they respond to treatment. In GAMT deficiency, GAA builds up while creatine falls. In AGAT deficiency, both GAA and creatine are low. In CTD, creatine is high in blood and urine but cannot reach the brain 1,2. The common clinical picture is intellectual disability, severe impairment of expressive speech, epilepsy and autistic behavior, with a movement disorder in GAMT deficiency 3,4,5,6 and a myopathy in AGAT deficiency 7,8. These disorders matter beyond their numbers because two of them are treatable, and they are counted among the inborn errors in which a diagnosis changes outcome 9,10.
This review covers five questions. How was creatine biology understood before the disorders were known? How were they discovered? How are patients found, by biochemistry and by spectroscopy? Why does losing creatine harm the brain? And how has treatment developed, from creatine supplementation to the therapies now in development for CTD? The bibliography behind it is shown as an interactive timeline in Figure 1.
Section 2
The chemistry needed to measure creatine is older than the field by a century. In 1886 Jaffe described the color reaction of creatinine with alkaline picrate 11, which was still being refined for creatinine measurement decades later 12. Later methods measured creatine directly with the diacetyl and α-naphthol reaction 13 and determined GAA among other guanidino compounds in biological fluids, later by chromatography 14,15. These assays later carried a trap. In GAMT deficiency, plasma creatinine measured by the Jaffe method can look normal when enzymatic or chromatographic methods show it is low 16.
Creatine's role in energy metabolism was established in muscle. In 1927 two groups found a labile phosphate compound in muscle, which Eggleton and Eggleton called phosphagen 17,18,19. It was identified as phosphocreatine 20. Creatine kinase, the enzyme that transfers phosphate between phosphocreatine and ADP, was crystallized in the 1950s 21. Brain and muscle were later found to carry distinct isoforms of the enzyme 22, and mitochondria carry their own 23,24.
The pathway of creatine synthesis was worked out in the 1940s and 1950s. Liver slices convert GAA (then called glycocyamine) into creatine 25,26, methionine was identified as the methyl donor 26, and glycine and arginine as precursors 27. Isotopes were used to measure the formation and loss of body creatine 28. The enzymatic mechanism of the methylation step was studied in 1954 29, and the transamidinase that forms GAA was purified 30. Creatine synthesis consumes a large share of the body's labile methyl groups and of arginine's amidino groups 31. Dietary creatine represses the transamidinase 32,33, and later work showed that this repression acts before translation 34. This feedback loop later became a lever for treating GAMT deficiency. Whether the brain makes its own creatine was asked as early as 1961 35. Creatine enters muscle by a saturable process 36, and the Walker review of 1979 consolidated the biosynthesis and its control 37.
The transporter itself was cloned in 1993. A cDNA from rabbit brain encoded a sodium- and chloride-dependent creatine transporter of the neurotransmitter transporter family 38. Human cDNAs followed 39,40. The gene was first mapped in mouse to a region conserved with human Xq28 40, and the human gene, SLC6A8, was assigned to Xq28 41,42. Human GAMT cDNA was cloned in 1995, prompted by the first patient suspected of a GAMT defect 43. A comprehensive review in 2000 summarized creatine and creatinine metabolism on the eve of the transporter and AGAT discoveries 44.
Two lines of theory explain why the brain should need creatine. The first is the phosphocreatine shuttle, the proposal that creatine kinase isoforms at sites of ATP production and use carry high-energy phosphate across the cell 24,45,46,47. Wallimann and colleagues extended this into the phosphocreatine circuit, for tissues with high and fluctuating energy demand 48. Energy budgets of the brain later showed that most of its energy is spent on signaling 49,50, which makes such a buffer plausible. Transmitting information is costly in ATP 51. Creatine also protects synaptic transmission during anoxia in brain slices 52. The second line treats creatine as a signaling molecule. Creatine is released from brain slices by an exocytotic, calcium-dependent process 53, and it has been found in synaptic vesicles 54. These ideas frame the disorders, but the corpus contains little direct evidence of which role matters most for the patients' symptoms.
Section 3
The disorders were discovered with an instrument built for other purposes. In 1974 phosphorus NMR spectra were first recorded from intact tissue 55. Surface coils then allowed phosphorus spectra from the muscle and brain of living animals 56, and in 1983 phosphocreatine was measured in the brains of newborn infants 57. Chemical shift imaging, which maps spectra across space, was proposed in 1982 58.
Proton spectroscopy brought the creatine peak itself into view. Proton spectra of rat brain in vivo were obtained in 1983 59, and localized proton spectra of human brain at 1.5 T in 1985 60. Single-voxel localization methods, STEAM and PRESS, made proton spectra routine in human brain on clinical scanners 61,62,63. The resonance at 3.03 ppm reflects creatine and phosphocreatine together 64,65. Spectral fitting methods, above all LCModel, turned these spectra into metabolite concentrations 66,67.
One habit of the field deserves emphasis, because the disorders exposed it. Early quantitative studies often assumed a fixed total creatine of about 10 mM and expressed other metabolites as ratios to it 64,68. Absolute quantification studies measured creatine directly and found that it varies with region and age 69,70,71. Ratios to an assumed stable creatine can add more variability than they remove 72,73. In a creatine deficiency, a creatine-referenced ratio is not just noisy but misleading, because the reference itself is missing. Developmental norms for children, measured from the 1990s on, set the baseline against which a low creatine peak can be judged 74,70,75.
Section 4
GAMT deficiency was the first of the three to be found. In 1994 Stöckler and colleagues described a child with an extrapyramidal movement disorder and very low serum and urine creatinine. Proton MRS showed generalized depletion of brain creatine, and phosphorus MRS showed no phosphocreatine 76. Oral arginine raised brain GAA without raising creatine, whereas oral creatine raised brain creatine and lowered GAA. The authors presented it as a new and treatable inborn error. In 1996 the same group showed severe GAMT deficiency in liver and identified the mutant alleles 77, and reported that 25 months of creatine normalized brain creatine with substantial clinical improvement 78. Further patients followed with epilepsy and global delay 79,80. A milder presentation, with nonspecific intellectual disability and behavioral problems, was recognized in 2000 81.
CTD was found in 2001 from the opposite biochemical signature. Cecil and colleagues described a patient whose brain creatine was deficient on MRS while serum and urine creatine were high and GAA was normal. Oral creatine produced no measurable rise in brain creatine and no clinical improvement, and the authors proposed a defect of the creatine transporter 1. Salomons and colleagues reported an X-linked creatine deficiency syndrome in a boy with absent brain creatine, a hemizygous nonsense mutation in SLC6A8 and fibroblasts that could not take up creatine 2. Three heterozygous female relatives had mild biochemical abnormalities. Further families followed within two years 82,83,84.
AGAT deficiency was found the same year, after spectroscopy flagged two sisters. In 2000 Bianchi and colleagues described sisters with intellectual disability and severe language delay whose blood tests, metabolic screening and MRI were normal. Only proton MRS revealed generalized brain creatine depletion, which almost completely reversed with oral creatine 85. In 2001 Item and colleagues identified the cause as AGAT deficiency, with a homozygous nonsense mutation and low urinary GAA 86. A third patient was found in the same Italian pedigree 87. By 2003 the three disorders were reviewed as one group 3,4.
The order of discovery reflects the instrument. In all three disorders, the first sign that pointed to creatine was the absent or reduced creatine peak on brain MRS. The routine blood and urine tests of the time did not reveal them.
Section 5
Creatine transporter deficiency. CTD is by far the most studied of the three in this corpus. Early descriptions established the core phenotype of developmental delay, severe expressive language impairment and mild epilepsy, with absent brain creatine 82,83,88 but preserved muscle creatine 88,89. Autistic behavior was listed among the hallmarks by 2003 90 and confirmed in further patients 91. Later reports added severe epilepsy 92, progressive intestinal and psychiatric problems in adult males 93 and cardiac findings 94. The largest retrospective series, 101 males from 85 families, found moderate to severe intellectual disability in most, with marked speech delay, behavioral problems, seizures, motor dysfunction and gastrointestinal problems 95. A third of these males had de novo mutations, and missense mutations with residual activity may give milder phenotypes.
Prospective natural history studies are recent. A study of 31 patients, compared with patients with fragile X syndrome, found symptoms before 24 months in most and a consistently delayed developmental trajectory 96. The Vigilan study followed 50 males aged 6 months to 65 years for up to four years 97. Most had significant intellectual disability, seizures, gastrointestinal symptoms and growth failure, all walked, and 78% developed some speech. Feeding problems combined with delayed sitting or crawling before the first birthday have been proposed as early signs that should prompt a urine screen 98. Cardiac findings remain unsettled. A cross-sectional study found a prolonged QTc in 39% of 18 males 99, whereas a later study of 23 males found prominent U-waves but no prolonged QTc once U-waves were excluded 100.
Females are the hardest group to diagnose. Heterozygous females in the first families already showed mild intellectual disability, learning problems or language impairments 2,82,88. A study of eight Dutch heterozygotes found raised urine creatine in only three, brain creatine that overlapped with controls, and skewed X-inactivation that made fibroblast uptake assays unreliable 101. A review of 32 reported female cases concluded that diagnosis in females requires molecular testing 102. A family survey found a mean age at diagnosis of 11.8 years in girls, after a mean age of 1.8 years at onset 103.
Interpreting SLC6A8 variants has its own literature. A fibroblast uptake assay classified missense variants as pathogenic or benign 104, and all known missense variants were classified functionally, with all variants deposited in a public database 105. Many pathogenic variants impair the processing and trafficking of the protein 106,107,108. The female carrier frequency was estimated at 0.024% from population exome data 109. In 2024 a ClinGen expert panel published gene-specific variant classification rules for GAMT, GATM and SLC6A8 110.
GAMT deficiency. A series of 27 patients found intellectual disability, epilepsy, GAA accumulation and brain creatine deficiency in all, with severe disability in 78% 111. Phenotype did not track genotype. A 2014 study of 48 individuals reported movement disorder in 13 and epilepsy in 35, and issued recommendations for diagnosis, treatment and monitoring 112. Epilepsy occurred in 81% of 58 reported cases and was drug-resistant in about 45% 113. A founder mutation, c.59G>C, accounts for most Portuguese alleles 114, and patients have been identified as adults in institutions for severe mental handicap 115. Estimates of frequency vary: a carrier frequency of 0.123% from exome data 116, an incidence near 1 in 250,000 from newborn sequencing 117, and a birth prevalence of 0.5 to 2 per million in the evidence review for newborn screening 118.
AGAT deficiency. AGAT deficiency is the rarest of the three. An international survey of 16 patients found intellectual or developmental disability in 15 and myopathy in 8 7. The myopathy can be prominent, presents in adulthood, and responds well to creatine 119,120,121,8. Febrile seizures had been noted in all three disorders 122, and focal epilepsy has been added to the AGAT phenotype recently 123,124. A separate, dominant disease of the same gene was found in 2018: heterozygous GATM missense variants cause renal Fanconi syndrome and kidney failure through aggregation of the enzyme in mitochondria 125.
Section 6
Biochemical diagnosis rests on three metabolites: GAA, creatine and creatinine. GAA is high in GAMT deficiency and low in AGAT deficiency 126,4. The urine creatine-to-creatinine ratio is high in males with CTD 82,127. Low serum and urine creatinine was the first biochemical clue to GAMT deficiency 76,78. In 1997, low 24-hour urinary creatinine and raised urinary GAA, detected with the Sakaguchi reaction 128, were proposed as screening tools 129, and chromatography confirmed high GAA in all body fluids 130. Stable-isotope-dilution mass spectrometry made the measurement precise 131, and tandem mass spectrometry and HPLC methods made it fast and applicable to dried blood spots 132,133,134. A 2004 study established age-dependent reference values and called the raised urine creatine-to-creatinine ratio a pathognomonic marker of CTD 127. Enzyme assays in cultured cells confirm the synthesis defects 135,86,136,137, and a fibroblast uptake assay confirms CTD 2,82,104.
Each marker has known failure modes. A diet rich in beef or oily fish raises the urine creatine ratio and causes false positives 138. In a series of 41 patients, plasma GAA was fully specific for both synthesis defects but less sensitive for AGAT deficiency, and the urine ratio was fully specific in males with CTD but insensitive in females 139. Plasma can also reveal CTD, mainly through a markedly decreased plasma creatinine 140. Laboratory practice was standardized in a 2017 technical standard of the American College of Medical Genetics and Genomics 141.
Screening of high-risk groups set the prevalence estimates. Sequencing of a European panel of families with X-linked intellectual disability found SLC6A8 mutations in at least 2.1% 142, and sequencing of 478 males with unexplained intellectual disability suggested about 1% 143. Urine screening of 1,600 males found four confirmed cases 138, and screening of 6,353 French patients with unexplained neurological symptoms found a prevalence of 0.25% for all creatine deficiencies 144. Screening children with nonsyndromic autism found no cases among 443 145. Guidelines for the evaluation of developmental delay have moved accordingly. A 2003 practice parameter did not recommend routine metabolic screening 146, whereas later reviews placed creatine disorders among the treatable conditions worth testing for 147,9.
Newborn screening is the main change of the last decade, and it applies to GAMT deficiency. GAA was raised in the neonatal blood spot of a GAMT patient as early as 2001 133, and neonatal screening was judged feasible the same year 132. A neonate treated before symptoms developed normally 148, and archived blood spots of further cases confirmed the signal 149. Pilot studies measured GAA in 3,000 and then 10,000 newborn blood spots, using a second-tier test to remove false positives 150,151. A three-tier program in British Columbia screened 135,372 newborns with only three referred for genotyping 152. The first infants identified prospectively were reported from Utah and New York in 2021, both treated by two weeks of age and developing normally 153. An alternative product ion cut second-tier testing by 98% in New York 154. The evidence review behind adding GAMT deficiency to the US Recommended Uniform Screening Panel was published in 2023 118. No comparable newborn screen exists for CTD in this corpus, and the urine ratio's insensitivity in females is one obstacle.
Section 7
MRS is the only test that looks directly at brain creatine, which is the deficit all three disorders share. In each of the discovery papers it was the decisive observation 76,85,1. It remains part of every diagnostic algorithm in the corpus, alongside the body-fluid markers and genetic testing 155,156. A review in 2017 set out its uses: measuring creatine and phosphocreatine by proton MRS, estimating creatine kinase flux by phosphorus MRS, and following treatment 157.
The spectra carry more than a missing peak. In GAMT deficiency, GAA itself can be seen, first in single-voxel spectra 76,129 and then with chemical shift imaging, which showed GAA more prominent in gray than white matter 158. Spectroscopic imaging can quantify the deficit directly. In one family, total creatine was 1.6 mM in an affected boy, 4.6 mM in his heterozygous sister and 7.5 mM in controls 159. Muscle spectroscopy separates the disorders further. Phosphorus MRS showed no phosphocreatine in the muscle of an adult with GAMT deficiency 160, whereas muscle creatine was normal in a patient with CTD 89. This difference supports separate routes of creatine supply to brain and muscle 161.
MRS has two limits as a screen. In heterozygous females, brain creatine reductions are smaller and variable, and individual values can overlap with controls 101,162. As a general test in developmental delay, its yield is low in children without neurological signs: in one cohort of 109 children, MRI or MRS contributed to a diagnosis in 9% and MRS was diagnostic in one 163. A single-center review found 2 of 14 males referred for MRI with global developmental delay had brain creatine deficiency 164. MRS is therefore most useful when the clinical picture or the urine markers already point to a creatine disorder, and when a female carrier needs a functional read-out.
MRS is also the main biomarker of treatment. It documented the restoration of brain creatine in GAMT and AGAT deficiency within the first reports 76,78,85. Serial proton and phosphorus spectra showed that brain creatine recovers less completely in GAMT than in AGAT deficiency, and better once blood GAA is lowered 165. Fourteen years of quantitative follow-up in one GAMT patient showed brain creatine rising without reaching control ranges 166. In CTD, the absence of a rise on MRS has been the standard evidence that a treatment failed to reach the brain 1,167,168. Brain creatine on MRS is one of the seven outcomes in the 2025 core outcome set for trials in CTD and GAMT deficiency 169. A 2026 proposal calls for a harmonized pediatric MRS protocol, after a review found that the acquisitions in patients' radiology reports vary 170.
A newer route images creatine through chemical exchange saturation transfer (CrCEST). The fast exchange of creatine's amine protons makes it possible to image creatine with little contribution from phosphocreatine 171. CrCEST was first applied to skeletal muscle 172. GAMT knockout mice, which lack brain creatine, were then used to separate the creatine signal from protein signals in brain 173,174. At 7 T in human brain, the signal mixes creatine with other contributions 175. In 26 volunteers at 3 T, the guanidinium CEST signal correlated with MRS-measured total creatine at r = 0.66 176. These methods promise maps of creatine at high resolution, but none in this corpus has yet been applied to patients with a creatine deficiency.
Section 8
The brain gets creatine from two sources, and the disorders show how the two interact. Creatine crosses the blood-brain barrier through SLC6A8 against a concentration gradient 177, but the entry is limited: after a large injection in rats, brain creatine rose only slightly 178. The brain also synthesizes creatine. AGAT, GAMT and SLC6A8 are expressed in neurons and glia throughout the rat brain 179, but fewer than 20% of cells co-express both synthetic enzymes, so GAA must often pass between cells to become creatine 180,181. The transporter appears to be absent from the astrocytes that line the barrier, which could explain why the brain depends on its own synthesis 179,180,182. This architecture explains the clinical split. Oral creatine reaches the brain through SLC6A8, which is intact in the synthesis defects. In CTD, local synthesis cannot compensate, because cells also need the transporter to take up creatine made by their neighbors.
GAMT deficiency adds a second mechanism, the accumulation of GAA. Guanidino compounds were known convulsants long before the disorders: γ-guanidinobutyric acid causes seizures 183, and guanidino compounds raised in uremia inhibit GABA and glycine responses 184. In 2002, GAA was shown to activate GABA-A receptors 185, and GAA is a potent GABA mimetic at cerebellar granule cells 186. But the evidence is mixed. Activation in cultured cerebellar granule cells required millimolar GAA 187, and GAA was not epileptogenic in neuronal networks or hippocampal slices at patient-relevant concentrations 188,189. In Gamt mutant mice, by contrast, systemic GAA affects GABA-A receptor function and seizure threshold 190. How much of the epilepsy in GAMT deficiency is due to GAA, rather than to creatine loss, is still open.
Animal models reproduce the deficit and many of its effects. GAMT-deficient mice showed high GAA and low creatine 191,192, with low body weight and impaired fertility 192. Ubiquitous Slc6a8 knockout mice lack brain and muscle creatine and show cognitive deficits 193,194. A brain-specific knockout was developed in 2012 195, and brain-specific knockouts reproduce the cognitive deficits with normal peripheral creatine 196,197. Deleting Slc6a8 on postnatal day 5 caused cognitive deficits, whereas deleting it on day 60 did not 198, which suggests a developmental window. A knock-in rat with the patient mutation Y389C adds a second species 199. CTD mice share EEG abnormalities with patients 200, and transcriptomics points to particular vulnerability of parvalbumin interneurons 201. Organoids from patients' stem cells reproduce neuronal deficits in a human system 202.
The models also show what creatine loss does not do. GAMT knockout mice run as far as controls and respond normally to myocardial infarction 203. Muscle dystrophy in AGAT knockout mice is reversed by creatine 204. Phosphorus MRS in patients with CTD found low phosphocreatine without raised lactate or lowered pH 205. These results suggest that tissues adapt to living without creatine better than the energy-buffer theory would predict, and that the brain's vulnerability may lie in development, in particular cell types, or in roles beyond energy.
Section 9
The synthesis defects. Treatment began with the discovery itself. Oral creatine raised brain creatine in the first GAMT patient 76 and normalized it over 25 months of treatment 78. Creatine alone did not control every patient's seizures, so treatment turned to lowering GAA. Restricting dietary arginine was tried in 1998 206. In 2001, arginine restriction plus ornithine supplementation, which inhibits AGAT 207, lowered GAA and nearly abolished seizures in a girl who had not responded to creatine alone 208. Sodium benzoate was in use by 2006 148, and a retrospective analysis linked lower glycine and higher ornithine to lower GAA 209. The added value of each component is uncertain. In one patient, ornithine and creatine lowered CSF GAA by 80%, while 18 further months of arginine restriction lowered it by only another 8% 210. In a mouse model, creatine itself lowered GAA by repressing AGAT 211, the same feedback first described in 1959 32.
The decisive result for the synthesis defects is that early treatment can prevent the disease. A neonate with GAMT deficiency treated from birth had normal development at 14 months 148, and a boy with AGAT deficiency treated from four months developed normally, unlike his two sisters 212. Long-term data now support this. AGAT-deficient patients treated from 4 and 16 months had normal development at 10 and 11 years 7, and in GAMT deficiency, younger siblings treated earlier had distinctly better outcomes, with the two treated as neonates indistinguishable from healthy controls 213. In GAMT deficiency diagnosed later, a registry of 22 patients reported improved severity scores in 13 and seizure freedom in 11, but normal development in only one 214. Even adults respond: a woman who began creatine at 52 became seizure-free 215. This evidence is the rationale for newborn screening. New approaches for GAMT deficiency include liver-directed gene therapy, which normalized plasma creatine and lowered GAA in mice 216, and CNS-directed gene therapy 217.
Creatine transporter deficiency. CTD has resisted treatment since its discovery, because oral creatine needs the missing transporter to reach the brain 1. The first strategy was to stimulate the brain's own synthesis with the precursors arginine and glycine. Results have been mixed. One boy improved on arginine with a rise in brain creatine 218, whereas four boys on arginine for nine months did not 219. Combined creatine, arginine and glycine produced no lasting brain creatine rise or cognitive gain in nine boys followed for four to six years 167, and helped only muscular symptoms in six severely affected patients 168. A systematic review of 28 cases found that 36% responded with a rise in brain creatine or clinical improvement 220. In an international registry, no male on combined therapy improved or deteriorated, while two of three females improved, which suggests the combination may halt progression in males 221. Several females have improved markedly on the combination 222,102,223, as has a boy with a hypomorphic variant, although his brain creatine did not rise 224. Glycine and arginine can raise homocysteine, which requires monitoring 225.
The second strategy is a creatine analog or prodrug that can cross membranes without the transporter. Creatine ethyl ester raised creatine uptake in patient fibroblasts but did not help four patients or raise their brain creatine 226. It degrades rapidly to creatinine 227. Cyclocreatine, a creatine analog, improved cognition in brain-specific knockout mice 195 and later improved cognitive, autistic and epileptic features in a mouse model 228. Its development has stalled on toxicity, however. Chronic dosing caused seizures and brain lesions in rats 229, and a dog study was terminated early because of severe toxicity 230. Cyclocreatine also enters cells mainly through SLC6A8 itself 231, which weakens the rationale for using it to bypass the transporter.
Dodecyl creatine ester (DCE) is the leading prodrug in the corpus. Among a series of creatine fatty esters, DCE raised creatine 20-fold in fibroblasts from patients with CTD 232. Packaged in lipid nanocapsules, it crossed an in vitro blood-brain barrier model 233. As an intranasal nanoemulsion, it improved object recognition and raised striatal ATP in Slc6a8 knockout mice 234. Studies in several species, including non-human primates, showed that intranasal DCE reaches neurons by the nose-to-brain pathway 235. Biomarkers of response have been proposed from proteomics, FDG-PET and DNA methylation in treated mice 236,237,238. No clinical efficacy data for DCE are in this corpus.
The third strategy restores the transporter. Many pathogenic variants misfold and are retained in the endoplasmic reticulum. The chemical chaperone 4-phenylbutyrate rescued several of these variants in cells 106, and drug-like correctors that bind SLC6A8 rescued creatine uptake for 10 to 20 percent of common missense variants and raised brain creatine in knock-in mice 239. Gene therapy is the most direct route. Intracisternal delivery of Slc6a8 in knock-in rats restored creatine in the hindbrain and prevented locomotor defects but did not correct forebrain phenotypes 240. Perinatal gene transfer in knockout mice prevented juvenile hypoconnectivity in functional MRI but left early cognitive deficits 241. A different idea bypasses the transporter by delivering the two synthetic enzymes, which raised creatine up to 11.6-fold in patient fibroblasts 242.
The field is now preparing for trials. A prospective natural history study provides the control data 97, a core outcome set defines what trials should measure 169, and a parent-led advocacy organization has supported registries, specimen repositories and newborn screening 243. A 2022 review summarized the state of treatment: AGAT and GAMT deficiency respond to high-dose oral creatine, and current treatments help about one third of patients with CTD 244.
Section 10
Five questions stand out from this corpus. First, what part of the brain damage is due to the loss of creatine's energy-buffer function, and what part to its other roles or to GAA? The mouse models show surprising tolerance of creatine loss in muscle and heart, which sharpens the question for the brain. Second, is there a developmental window for CTD therapy? The neonatal-versus-adult deletion result in mice suggests there is, and gene therapy results so far correct some phenotypes but not others. Third, can CTD be found early? Newborn screening works for GAMT deficiency, but CTD has no established newborn screen, and the urine marker misses many females. Fourth, can MRS become a quantitative trial endpoint? That requires harmonized acquisition and quantification that does not depend on creatine as an internal reference. Fifth, which of the CTD candidates will reach patients? Cyclocreatine stalled on toxicity, DCE has animal and primate data but no published clinical results here, and correctors and gene therapy are preclinical. The history of the synthesis defects suggests that if a therapy reaches the brain early enough, outcomes can be transformed.
A note on sources
This review was written from abstract-derived summaries, so it cannot report what papers said only in their methods, figures or discussion. About 60 papers in the corpus, most of them published before 1975, had no abstract available; their summaries restate only the title, and the review cites them only for what the title establishes. Abstracts compress results and can overstate them, and where two studies disagree, for example on the cardiac findings in CTD or on GAA toxicity, the review reports the disagreement rather than resolving it.
The bibliography is broad but not exhaustive. It was built by nine search lanes, a cross-citation pass and a forward-citation pass, and its numbers and dates are those in the summaries. Clinical trials registered but not yet published are outside its scope, so the status of human trials of DCE or gene therapy for CTD may have moved beyond what is described here. Citation counts and the most recent papers, from 2025 and 2026, are snapshots as of October 2026.
References
Numbered in order of first appearance. The monospace code is the reference's
identifier in the corpus, so any entry can be looked up in rows.json, the
spreadsheet or the timeline. Citation counts are OpenAlex values recorded when the
bibliography was built.
Cecil, K. M., Salomons, G. S., Ball, W. S., Wong, B., Chuck, G., Verhoeven, N. M., Jakobs, C., & DeGrauw, T. J. (2001). Irreversible brain creatine deficiency with elevated serum and urine creatine: A creatine transporter defect? Annals of Neurology, 49(3), 401-404.
Salomons, G. S., van Dooren, S. J. M., Verhoeven, N. M., Cecil, K. M., Ball, W. S., Degrauw, T. J., & Jakobs, C. (2001). X-linked creatine-transporter gene (SLC6A8) defect: A New creatine-deficiency syndrome. The American Journal of Human Genetics, 68(6), 1497-1500.
Schulze, A. (2003). Creatine deficiency syndromes. Molecular and Cellular Biochemistry, 244(1-2), 143-150.
Stromberger, C., Bodamer, O. A., & Stöckler-Ipsiroglu, S. (2003). Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. Journal of Inherited Metabolic Disease, 26(2-3), 299-308.
Stockler, S., Schutz, P. W., & Salomons, G. S. (2007). Cerebral creatine deficiency syndromes: Clinical aspects, treatment and pathophysiology. In G. S. Salomons & M. Wyss (Eds.), Creatine and creatine kinase in health and disease (Subcellular Biochemistry, Vol. 46, pp. 149-166). Springer.
Schulze, A. (2013). Creatine deficiency syndromes. In O. Dulac, M. Lassonde, & H. B. Sarnat (Eds.), Handbook of clinical neurology: Vol. 113. Pediatric neurology part III (pp. 1837-1843). Elsevier.
Stockler-Ipsiroglu, S., Apatean, D., Battini, R., DeBrosse, S., Dessoffy, K., Edvardson, S., Eichler, F., Johnston, K., Koeller, D. M., Nouioua, S., Tazir, M., Verma, A., Dowling, M. D., Wierenga, K. J., Wierenga, A. M., Zhang, V., & Wong, L.-J. C. (2015). Arginine:glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide. Molecular Genetics and Metabolism, 116(4), 252-259.
Finezilber, Y., Massey, C., Radley, J. A., & Murphy, E. (2024). Arginine:glycine amidinotransferase (AGAT) deficiency: An easy-to-miss treatable adult-onset myopathy. Practical Neurology, 24(5), 413-416.
van Karnebeek, C. D. M., & Stockler, S. (2012). Treatable inborn errors of metabolism causing intellectual disability: A systematic literature review. Molecular Genetics and Metabolism, 105(3), 368-381.
Stockler-Ipsiroglu, S., & van Karnebeek, C. D. M. (2014). Cerebral creatine deficiencies: A group of treatable intellectual developmental disorders. Seminars in Neurology, 34(03), 350-356.
Jaffe, M. (1886). Ueber den Niederschlag, welchen Pikrinsäure in normalem Harn erzeugt und über eine neue Reaction des Kreatinins. bchm, 10(5), 391-400.
Bonsnes, R. W., & Taussky, H. H. (1945). On the colorimetric determination of creatinine by the Jaffe reaction. Journal of Biological Chemistry, 158(3), 581-591.
Eggleton, P., Elsden, S. R., & Gough, N. (1943). The estimation of creatine and of diacetyl. Biochemical Journal, 37(5), 526-529.
Van Pilsum, J. F., Martin, R. P., Kito, E., & Hess, J. (1956). Determination of creatine, creatinine, arginine, guanidinoacetic acid, guanidine, and methyl-guanidine in biological fluids. Journal of Biological Chemistry, 222(1), 225-236.
Yamamoto, Y., Manji, T., Saito, A., Maeda, K., & Ohta, K. (1979). Ion-exchange chromatographic separation and fluorometric detection of guanidino compounds in physiologic fluids. Journal of Chromatography B: Biomedical Sciences and Applications, 162(3), 327-340.
Verhoeven, N. M., Guérand, W. S., Struys, E. A., Bouman, A. A., van der Knaap, M. S., & Jakobs, C. (2000). Plasma creatinine assessment in creatine deficiency: A diagnostic pitfall. Journal of Inherited Metabolic Disease, 23(8), 835-840.
Fiske, C. H., & Subbarow, Y. (1927). The nature of the "inorganic phosphate" in voluntary muscle. Science, 65(1686), 401-403.
Eggleton, P., & Eggleton, G. P. (1927). The inorganic phosphate and a labile form of organic phosphate in the gastrocnemius of the frog. Biochemical Journal, 21(1), 190-195.
Eggleton, P., & Eggleton, G. P. (1927). The physiological significance of ‘phosphagen’. The Journal of Physiology, 63(2), 155-161.
Fiske, C. H., & Subbarow, Y. (1929). Phosphocreatine. Journal of Biological Chemistry, 81(3), 629-679.
Kuby, S. A., Noda, L., & Lardy, H. A. (1954). Adenosinetriphosphate-creatine transphosphorylase. Journal of Biological Chemistry, 209(1), 191-201.
Eppenberger, H. M., Dawson, D. M., & Kaplan, N. O. (1967). The comparative enzymology of creatine kinases. Journal of Biological Chemistry, 242(2), 204-209.
Jacobs, H., Heldt, H. W., & Klingenberg, M. (1964). High activity of creatine kinase in mitochondria from muscle and brain and evidence for a separate mitochondrial isoenzyme of creatine kinase. Biochemical and Biophysical Research Communications, 16(6), 516-521.
Jacobus, W. E., & Lehninger, A. L. (1973). Creatine kinase of rat heart mitochondria. Journal of Biological Chemistry, 248(13), 4803-4810.
Borsook, H., & Dubnoff, J. W. (1940). The formation of creatine from glycocyamine in the liver. Journal of Biological Chemistry, 132(2), 559-574.
Borsook, H., & Dubnoff, J. W. (1941). The formation of glycocyamine in animal tissues. Journal of Biological Chemistry, 138(1), 389-403.
Bloch, K., & Schoenheimer, R. (1941). The biological precursors of creatine. Journal of Biological Chemistry, 138(1), 167-194.
Bloch, K., Schoenheimer, R., & Rittenberg, D. (1941). Rate of formation and disappearance of body creatine in normal animals. Journal of Biological Chemistry, 138(1), 155-166.
Cantoni, G. L., & Vignos, P. J. (1954). Enzymatic mechanism of creatine synthesis. Journal of Biological Chemistry, 209(2), 647-659.
Ratner, S., & Rochovansky, O. (1956). Biosynthesis of guanidinoacetic acid. I. Purification and properties of transamidinase. Archives of Biochemistry and Biophysics, 63(2), 277-295.
Brosnan, J. T., da Silva, R. P., & Brosnan, M. E. (2011). The metabolic burden of creatine synthesis. Amino Acids, 40(5), 1325-1331.
Walker, J. B. (1959). Repression of arginine-glycine transamidinase activity by dietary creatine. Biochimica et Biophysica Acta, 36(2), 574-575.
Walker, J. B. (1960). Metabolic control of creatine biosynthesis: I. Effect of dietary creatine. Journal of Biological Chemistry, 235(8), 2357-2361.
McGuire, D. M., Gross, M. D., Van Pilsum, J. F., & Towle, H. C. (1984). Repression of rat kidney L-arginine:glycine amidinotransferase synthesis by creatine at a pretranslational level. Journal of Biological Chemistry, 259(19), 12034-12038.
Defalco, A. J., & Davies, R. K. (1961). The synthesis of creatine by the brain of the intact rat*. Journal of Neurochemistry, 7(4), 308-312.
Fitch, C. D., & Shields, R. P. (1966). Creatine metabolism in skeletal muscle: I. Creatine movement across muscle membranes. Journal of Biological Chemistry, 241(15), 3611-3614.
Walker, J. B. (1979). Creatine: Biosynthesis, regulation, and function. Advances in Enzymology - and Related Areas of Molecular Biology.
Guimbal, C., & Kilimann, M. W. (1993). A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. Journal of Biological Chemistry, 268(12), 8418-8421.
Sora, I., Richman, J., Santoro, G., Wei, H. B., Wang, Y., Vanderah, T., Horvath, R., Nguyen, M., Waite, S., Roeske, W. R., & Yamamura, H. I. (1994). The cloning and expression of a human creatine transporter. Biochemical and Biophysical Research Communications, 204(1), 419-427.
Nash, S. R., Giros, B., Kingsmore, S. F., Rochelle, J. M., Suter, S. T., Gregor, P., Seldin, M. F., & Caron, M. G. (1994). Cloning, pharmacological characterization, and genomic localization of the human creatine transporter. Receptors & Channels, 2(2), 165–174.
Gregor, P., Nash, S. R., Caron, M. G., Seldin, M. F., & Warren, S. T. (1995). Assignment of the creatine transporter gene (SLC6A8) to human chromosome Xq28 telomeric to G6PD. Genomics, 25(1), 332-333.
Sandoval, N., Bauer, D., Brenner, V., Coy, J. F., Drescher, B., Kioschis, P., Korn, B., Nyakatura, G., Poustka, A., Reichwald, K., Rosenthal, A., & Platzer, M. (1996). The genomic organization of a human creatine transporter (CRTR) gene located in Xq28. Genomics, 35(2), 383-385.
Isbrandt, D., & von Figura, K. (1995). Cloning and sequence analysis of human guanidinoacetate N-methyltransferase cDNA. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1264(3), 265-267.
Wyss, M., & Kaddurah-Daouk, R. (2000). Creatine and creatinine metabolism. Physiological Reviews, 80(3), 1107-1213.
Saks, V. A., Rosenshtraukh, L. V., Smirnov, V. N., & Chazov, E. I. (1978). Role of creatine phosphokinase in cellular function and metabolism. Canadian Journal of Physiology and Pharmacology, 56(5), 691-706.
Bessman, S. P., & Geiger, P. J. (1981). Transport of energy in muscle: The phosphorylcreatine shuttle. Science, 211(4481), 448-452.
Meyer, R. A., Sweeney, H. L., & Kushmerick, M. J. (1984). A simple analysis of the "phosphocreatine shuttle". American Journal of Physiology-Cell Physiology, 246(5), C365-C377.
Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992). Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The ‘phosphocreatine circuit’ for cellular energy homeostasis. Biochemical Journal, 281(1), 21-40.
Ames, A. (2000). CNS energy metabolism as related to function. Brain Research Reviews, 34(1-2), 42-68.
Attwell, D., & Laughlin, S. B. (2001). An energy budget for signaling in the grey matter of the brain. Journal of Cerebral Blood Flow & Metabolism, 21(10), 1133-1145.
Laughlin, S. B., de Ruyter van Steveninck, R. R., & Anderson, J. C. (1998). The metabolic cost of neural information. Nature Neuroscience, 1(1), 36-41.
Whittingham, T. S., & Lipton, P. (1981). Cerebral synaptic transmission during anoxia is protected by creatine. Journal of Neurochemistry, 37(6), 1618-1621.
Almeida, L. S., Salomons, G. S., Hogenboom, F., Jakobs, C., & Schoffelmeer, A. N. M. (2006). Exocytotic release of creatine in rat brain. Synapse, 60(2), 118-123.
Bian, X., Zhu, J., Jia, X., Liang, W., Yu, S., Li, Z., Zhang, W., & Rao, Y. (2023). Suggestion of creatine as a new neurotransmitter by approaches ranging from chemical analysis and biochemistry to electrophysiology. eLife, 12.
Hoult, D. I., Busby, S. J. W., Gadian, D. G., Radda, G. K., Richards, R. E., & Seeley, P. J. (1974). Observation of tissue metabolites using 31P nuclear magnetic resonance. Nature, 252(5481), 285-287.
Ackerman, J. J. H., Grove, T. H., Wong, G. G., Gadian, D. G., & Radda, G. K. (1980). Mapping of metabolites in whole animals by 31P NMR using surface coils. Nature, 283(5743), 167-170.
Cady, E. B., Dawson, M. J., Hope, P. L., Tofts, P. S., Costello, A. M. de L., Delpy, D. T., Reynolds, E. O. R., & Wilkie, D. R. (1983). Non-invasive investigation of cerebral metabolism in newborn infants by phosphorus nuclear magnetic resonance spectroscopy. The Lancet, 321(8333), 1059-1062.
Brown, T. R., Kincaid, B. M., & Ugurbil, K. (1982). NMR chemical shift imaging in three dimensions. Proceedings of the National Academy of Sciences, 79(11), 3523-3526.
Behar, K. L., den Hollander, J. A., Stromski, M. E., Ogino, T., Shulman, R. G., Petroff, O. A., & Prichard, J. W. (1983). High-resolution 1H nuclear magnetic resonance study of cerebral hypoxia in vivo. Proceedings of the National Academy of Sciences, 80(16), 4945-4948.
Bottomley, P. A., Edelstein, W. A., Foster, T. H., & Adams, W. A. (1985). In vivo solvent-suppressed localized hydrogen nuclear magnetic resonance spectroscopy: A window to metabolism? Proceedings of the National Academy of Sciences, 82(7), 2148-2152.
Frahm, J., Merboldt, K.-D., & Hänicke, W. (1987). Localized proton spectroscopy using stimulated echoes. Journal of Magnetic Resonance, 72(3), 502-508.
Bottomley, P. A. (1987). Spatial localization in NMR spectroscopy in vivo. Annals of the New York Academy of Sciences, 508(1), 333-348.
Frahm, J., Bruhn, H., Gyngell, M. L., Merboldt, K. D., Hänicke, W., & Sauter, R. (1989). Localized high-resolution proton NMR spectroscopy using stimulated echoes: Initial applications to human brain in vivo. Magnetic Resonance in Medicine, 9(1), 79-93.
Hanstock, C. C., Rothman, D. L., Prichard, J. W., Jue, T., & Shulman, R. G. (1988). Spatially localized 1H NMR spectra of metabolites in the human brain. Proceedings of the National Academy of Sciences, 85(6), 1821-1825.
Miller, B. L. (1991). A review of chemical issues in 1H NMR spectroscopy: N-acetyl-l-aspartate, creatine and choline. NMR in Biomedicine, 4(2), 47-52.
Provencher, S. W. (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine, 30(6), 672-679.
Provencher, S. W. (2001). Automatic quantitation of localized in vivo1H spectra with LCModel. NMR in Biomedicine, 14(4), 260-264.
Frahm, J., Bruhn, H., Gyngell, M. L., Merboldt, K. D., Hänicke, W., & Sauter, R. (1989). Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magnetic Resonance in Medicine, 11(1), 47-63.
Hennig, J., Pfister, H., Ernst, T., & Ott, D. (1992). Direct absolute quantification of metabolites in the human brain with in vivo localized proton spectroscopy. NMR in Biomedicine, 5(4), 193-199.
Kreis, R., Ernst, T., & Ross, B. D. (1993). Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magnetic Resonance in Medicine, 30(4), 424-437.
Pouwels, P. J. W., & Frahm, J. (1998). Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magnetic Resonance in Medicine, 39(1), 53-60.
Li, B. S. Y., Wang, H., & Gonen, O. (2003). Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magnetic Resonance Imaging, 21(8), 923-928.
Jansen, J. F. A., Backes, W. H., Nicolay, K., & Kooi, M. E. (2006). 1H MR spectroscopy of the brain: Absolute quantification of metabolites. Radiology, 240(2), 318-332.
van der Knaap, M. S., van der Grond, J., van Rijen, P. C., Faber, J. A., Valk, J., & Willemse, K. (1990). Age-dependent changes in localized proton and phosphorus MR spectroscopy of the brain. Radiology, 176(2), 509-515.
Pouwels, P. J. W., Brockmann, K., Kruse, B., Wilken, B., Wick, M., Hanefeld, F., & Frahm, J. (1999). Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS. Pediatric Research, 46(4), 474-474.
Stöckler, S., Holzbach, U., Hanefeld, F., Marquardt, I., Helms, G., Requart, M., Hänicke, W., & Frahm, J. (1994). Creatine deficiency in the brain: A New, treatable inborn error of metabolism. Pediatric Research, 36(3), 409-413.
Stöckler, S., Isbrandt, D., Hanefeld, F., Schmidt, B., & von Figura, K. (1996). Guanidinoacetate methyltransferase deficiency: The first inborn error of creatine metabolism in man. American Journal of Human Genetics, 58(5), 914–922.
Stöckler, S., Hanefeld, F., & Frahm, J. (1996). Creatine replacement therapy in guanidineoacetate methyltransferase deficiency, a novel inborn error of metabolism. The Lancet, 348(9030), 789-790.
Ganesan, V., Johnson, A., Connelly, A., Eckhardt, S., & Surtees, R. A. H. (1997). Guanidinoacetate methyltransferase deficiency: New clinical features. Pediatric Neurology, 17(2), 155-157.
Leuzzi, V., Bianchi, M. C., Tosetti, M., Carducci, C., Cerquiglini, A., Cioni, G., & Antonozzi, I. (2000). Brain creatine depletion: Guanidinoacetate methyltransferase deficiency (improving with creatine supplementation). Neurology, 55(9), 1407-1410.
van der Knaap, M. S., Verhoeven, N. M., Maaswinkel-Mooij, P., Pouwels, P. J. W., Onkenhout, W., Peeters, E. A. J., Stöckler-Ipsiroglu, S., & Jakobs, C. (2000). Mental retardation and behavioral problems as presenting signs of a creatine synthesis defect. Annals of Neurology, 47(4), 540-543.
Hahn, K. A., Salomons, G. S., Tackels-Horne, D., Wood, T. C., Taylor, H. A., Schroer, R. J., Lubs, H. A., Jakobs, C., Olson, R. L., Holden, K. R., Stevenson, R. E., & Schwartz, C. E. (2002). X-linked mental retardation with seizures and carrier manifestations is caused by a mutation in the creatine-transporter gene (SLC6A8) located in Xq28. The American Journal of Human Genetics, 70(5), 1349-1356.
deGrauw, T. J., Salomons, G. S., Cecil, K. M., Chuck, G., Newmeyer, A., Schapiro, M. B., & Jakobs, C. (2002). Congenital creatine transporter deficiency. Neuropediatrics, 33(5), 232-238.
Bizzi, A., Bugiani, M., Salomons, G. S., Hunneman, D. H., Moroni, I., Estienne, M., Danesi, U., Jakobs, C., & Uziel, G. (2002). X-linked creatine deficiency syndrome: A novel mutation in creatine transporter gene SLC6A8. Annals of Neurology, 52(2), 227-231.
Bianchi, M. C., Tosetti, M., Fornai, F., Alessandri, M. G., Cipriani, P., De Vito, G., & Canapicchi, R. (2000). Reversible brain creatine deficiency in two sisters with normal blood creatine level. Annals of Neurology, 47(4), 511-513.
Item, C. B., Stöckler-Ipsiroglu, S., Stromberger, C., Mühl, A., Alessandrì, M. G., Bianchi, M. C., Tosetti, M., Fornai, F., & Cioni, G. (2001). Arginine:Glycine amidinotransferase deficiency: The third inborn error of creatine metabolism in humans. The American Journal of Human Genetics, 69(5), 1127-1133.
Battini, R., Leuzzi, V., Carducci, C., Tosetti, M., Bianchi, M. C., Item, C. B., Stöckler-Ipsiroglu, S., & Cioni, G. (2002). Creatine depletion in a new case with AGAT deficiency: Clinical and genetic study in a large pedigree. Molecular Genetics and Metabolism, 77(4), 326-331.
deGrauw, T. J., Cecil, K. M., Byars, A. W., Salomons, G. S., Ball, W. S., & Jakobs, C. (2003). The clinical syndrome of creatine transporter deficiency. Molecular and Cellular Biochemistry, 244(1-2), 45-48.
Pyne-Geithman, G. J., deGrauw, T. J., Cecil, K. M., Chuck, G., Lyons, M. A., Ishida, Y., & Clark, J. F. (2004). Presence of normal creatine in the muscle of a patient with a mutation in the creatine transporter: A case study. Molecular and Cellular Biochemistry, 262(1-2), 35-39.
Salomons, G. S., Van Dooren, S. J. M., Verhoeven, N. M., Marsden, D., Schwartz, C., Cecil, K. M., DeGrauw, T. J., & Jakobs, C. (2003). X-linked creatine transporter defect: An overview. Journal of Inherited Metabolic Disease, 26(2-3), 309-318.
Póo-Argüelles, P., Arias, A., Vilaseca, M. A., Ribes, A., Artuch, R., Sans-Fito, A., Moreno, A., Jakobs, C., & Salomons, G. (2006). X-linked creatine transporter deficiency in two patients with severe mental retardation and autism. Journal of Inherited Metabolic Disease, 29(1), 220-223.
Mancardi, M. M., Caruso, U., Schiaffino, M. C., Baglietto, M. G., Rossi, A., Battaglia, F. M., Salomons, G. S., Jakobs, C., Zara, F., Veneselli, E., & Gaggero, R. (2007). Severe epilepsy in X-linked creatine transporter defect (CRTR-D). Epilepsia, 48(6), 1211-1213.
Kleefstra, T., Rosenberg, E., Salomons, G., Stroink, H., Van Bokhoven, H., Hamel, B., & De Vries, B. (2005). Progressive intestinal, neurological and psychiatric problems in two adult males with cerebral creatine deficiency caused by an SLC6A8 mutation. Clinical Genetics, 68(4), 379-381.
Anselm, I. A., Coulter, D. L., & Darras, B. T. (2008). Cardiac manifestations in a child with a novel mutation in creatine transporter gene slc6a8. Neurology, 70(18), 1642-1644.
van de Kamp, J. M., Betsalel, O. T., Mercimek-Mahmutoglu, S., Abulhoul, L., Grünewald, S., Anselm, I., Azzouz, H., Bratkovic, D., de Brouwer, A., Hamel, B., Kleefstra, T., Yntema, H., Campistol, J., Vilaseca, M. A., Cheillan, D., D’Hooghe, M., Diogo, L., Garcia, P., Valongo, C., … Salomons, G. S. (2013). Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. Journal of Medical Genetics, 50(7), 463-472.
Curie, A., Lion-François, L., Valayannopoulos, V., Perreton, N., Gavanon, M., Touil, N., Brun-Laurisse, A., Gheurbi, F., Buchy, M., Halep, H., Cheillan, D., Mercier, C., Brassier, A., Desnous, B., Kassai, B., De Lonlay, P., & Des Portes, V. (2024). Clinical characteristics, developmental trajectory, and caregiver burden of patients with creatine transporter deficiency ( SLC6A8 ). Neurology, 102(8).
Miller, J. S., Farmer, C., Blair, S., Bianconi, S., Akshoomoff, N., Anselm, I., Barshop, B. A., Becker, L., Bennett, A. E., Berry, L. N., Berry-Kravis, E. M., Bruchey, A., Byars, A. W., Cimms, T., Cecil, K. M., Covello, M., Cubit, L. S., Das, T., Davis, R. J., … Thurm, A. (2026). Longitudinal characterization of males with X-linked creatine transporter deficiency: Final results of a multiyear observational study. Pediatric Neurology, 175, 8-18.
Miller, J. S., Thomas, R. P., Bennett, A., Bianconi, S., Bruchey, A., Davis, R. J., Ficicioglu, C., Guthrie, W., Porter, F. D., & Thurm, A. (2019). Early indicators of creatine transporter deficiency. The Journal of Pediatrics, 206, 283-285.
Levin, M. D., Bianconi, S., Smith, A., Cawley, N. X., Do, A. D., Hammond, D., Grafstein, J. F., Thurm, A., Miller, J., Perreault, J., Noguchi, A., Springer, D., Kozel, B. A., Spurney, C. F., Wassif, C. A., Yu, Z.-X., Schulze, A., Porter, F. D., & Hannah-Shmouni, F. (2021). X-linked creatine transporter deficiency results in prolonged QTc and increased sudden death risk in humans and disease model. Genetics in Medicine, 23(10), 1864-1872.
Delinière, A., Mulatier, C., Cheillan, D., Gheurbi, F., Buchy, M., Dufay, N., Moulin-Zinsch, A., Bertail-Galoin, C., Sabour, M., Aarab, M., Perouse de Montclos, T., Ouvrier-Buffet, D., Boisson, A., Stos, B., Rharbaoui, M., Remerand, G., Barnerias, C., Brassier, A., Goldenberg, A., … Curie, A. (2026). Prominent U-waves without QT prolongation in X-linked creatine transporter deficiency caused by SLC6A8 variants. Heart Rhythm, 23(3), 700-709.
van de Kamp, J., Mancini, G., Pouwels, P., Betsalel, O., van Dooren, S., de Koning, I., Steenweg, M., Jakobs, C., van der Knaap, M., & Salomons, G. (2011). Clinical features and X-inactivation in females heterozygous for creatine transporter defect. Clinical Genetics, 79(3), 264-272.
Mejdahl Nielsen, M., Petersen, E. T., Fenger, C. D., Ørngreen, M. C., Siebner, H. R., Boer, V. O., Považan, M., Lund, A., Grønborg, S. W., & Hammer, T. B. (2023). X-linked creatine transporter (SLC6A8) deficiency in females: Difficult to recognize, but a potentially treatable disease. Molecular Genetics and Metabolism, 140(3), 107694.
Chehowah, C., Mittelman, A., & des Portes, V. (2025). An international questionnaire highlights and supports the case for including girls in creatine transporter deficiency research. Frontiers in Neuroscience, 19.
Rosenberg, E. H., Martínez Muñoz, C., Betsalel, O. T., van Dooren, S. J. M., Fernandez, M., Jakobs, C., deGrauw, T. J., Kleefstra, T., Schwartz, C. E., & Salomons, G. S. (2007). Functional characterization of missense variants in the creatine transporter gene (SLC6A8): Improved diagnostic application. Human Mutation, 28(9), 890-896.
Betsalel, O. T., Pop, A., Rosenberg, E. H., Fernandez-Ojeda, M., Jakobs, C., & Salomons, G. S. (2012). Detection of variants in SLC6A8 and functional analysis of unclassified missense variants. Molecular Genetics and Metabolism, 105(4), 596-601.
El-Kasaby, A., Kasture, A., Koban, F., Hotka, M., Asjad, H. M. M., Kubista, H., Freissmuth, M., & Sucic, S. (2019). Rescue by 4-phenylbutyrate of several misfolded creatine transporter-1 variants linked to the creatine transporter deficiency syndrome. Neuropharmacology, 161, 107572.
Salazar, M. D., Zelt, N. B., Saldivar, R., Kuntz, C. P., Chen, S., Penn, W. D., Bonneau, R., Koehler Leman, J., & Schlebach, J. P. (2020). Classification of the molecular defects associated with pathogenic variants of the SLC6A8 creatine transporter. Biochemistry, 59(13), 1367-1377.
Ferrada, E., Wiedmer, T., Wang, W.-A., Frommelt, F., Steurer, B., Klimek, C., Lindinger, S., Osthushenrich, T., Garofoli, A., Brocchetti, S., Bradberry, S., Huang, J., MacNamara, A., Scarabottolo, L., Ecker, G. F., Malarstig, A., & Superti-Furga, G. (2024). Experimental and computational analysis of newly identified pathogenic mutations in the creatine transporter SLC6A8. Journal of Molecular Biology, 436(2), 168383.
DesRoches, C.-L., Patel, J., Wang, P., Minassian, B., Salomons, G. S., Marshall, C. R., & Mercimek-Mahmutoglu, S. (2015). Estimated carrier frequency of creatine transporter deficiency in females in the general population using functional characterization of novel missense variants in the SLC6A8 gene. Gene, 565(2), 187-191.
Goldstein, J., Thomas-Wilson, A., Groopman, E., Aggarwal, V., Bianconi, S., Fernandez, R., Hart, K., Longo, N., Liang, N., Reich, D., Wallis, H., Weaver, M., Young, S., & Mercimek-Andrews, S. (2024). ClinGen variant curation expert panel recommendations for classification of variants in GAMT, GATM and SLC6A8 for cerebral creatine deficiency syndromes. Molecular Genetics and Metabolism, 142(1), 108362.
Mercimek-Mahmutoglu, S., Stoeckler-Ipsiroglu, S., Adami, A., Appleton, R., Araújo, H. C., Duran, M., Ensenauer, R., Fernandez-Alvarez, E., Garcia, P., Grolik, C., Item, C. B., Leuzzi, V., Marquardt, I., Mühl, A., Saelke-Kellermann, R. A., Salomons, G. S., Schulze, A., Surtees, R., van der Knaap, M. S., … Jakobs, C. (2006). GAMT deficiency: Features, treatment, and outcome in an inborn error of creatine synthesis. Neurology, 67(3), 480-484.
Stockler-Ipsiroglu, S., van Karnebeek, C., Longo, N., Korenke, G. C., Mercimek-Mahmutoglu, S., Marquart, I., Barshop, B., Grolik, C., Schlune, A., Angle, B., Araújo, H. C., Coskun, T., Diogo, L., Geraghty, M., Haliloglu, G., Konstantopoulou, V., Leuzzi, V., Levtova, A., MacKenzie, J., … Schulze, A. (2014). Guanidinoacetate methyltransferase (GAMT) deficiency: Outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. Molecular Genetics and Metabolism, 111(1), 16-25.
Mikati, A. G., Gheida, I. A., Shamseddine, A., Mikati, M. A., & Karam, P. E. (2013). Epileptic and electroencephalographic manifestations of guanidinoacetate-methyltransferase deficiency. Epileptic Disorders, 15(4), 407-416.
Almeida, L. S., Vilarinho, L., Darmin, P. S., Rosenberg, E. H., Martinez-Muñoz, C., Jakobs, C., & Salomons, G. S. (2007). A prevalent pathogenic GAMT mutation (c.59G>C) in Portugal. Molecular Genetics and Metabolism, 91(1), 1-6.
Caldeira Araújo, H., Smit, W., Verhoeven, N. M., Salomons, G. S., Silva, S., Vasconcelos, R., Tomás, H., Almeida, I. T. D., Jakobs, C., & Duran, M. (2005). Guanidinoacetate methyltransferase deficiency identified in adults and a child with mental retardation. American Journal of Medical Genetics Part A, 133A(2), 122-127.
Desroches, C.-L., Patel, J., Wang, P., Minassian, B., Marshall, C. R., Salomons, G. S., & Mercimek-Mahmutoglu, S. (2015). Carrier frequency of guanidinoacetate methyltransferase deficiency in the general population by functional characterization of missense variants in the GAMT gene. Molecular Genetics and Genomics, 290(6), 2163-2171.
Mercimek-Mahmutoglu, S., Pop, A., Kanhai, W., Fernandez Ojeda, M., Holwerda, U., Smith, D., Loeber, J. G., Schielen, P. C. J. I., & Salomons, G. S. (2016). A pilot study to estimate incidence of guanidinoacetate methyltransferase deficiency in newborns by direct sequencing of the GAMT gene. Gene, 575(1), 127-131.
Ream, M. A., Lam, W. K. K., Grosse, S. D., Ojodu, J., Jones, E., Prosser, L. A., Rose, A. M., Comeau, A. M., Tanksley, S., Powell, C. M., & Kemper, A. R. (2023). Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics, 152(2).
Edvardson, S., Korman, S. H., Livne, A., Shaag, A., Saada, A., Nalbandian, R., Allouche-Arnon, H., Gomori, J. M., & Katz-Brull, R. (2010). L-arginine:glycine amidinotransferase (AGAT) deficiency: Clinical presentation and response to treatment in two patients with a novel mutation. Molecular Genetics and Metabolism, 101(2-3), 228-232.
Verma, A. (2010). Arginine:glycine amidinotransferase deficiency: A treatable metabolic encephalomyopathy. Neurology, 75(2), 186-188.
Nouioua, S., Cheillan, D., Zaouidi, S., Salomons, G. S., Amedjout, N., Kessaci, F., Boulahdour, N., Hamadouche, T., & Tazir, M. (2013). Creatine deficiency syndrome. A treatable myopathy due to arginine–glycine amidinotransferase (AGAT) deficiency. Neuromuscular Disorders, 23(8), 670-674.
Leuzzi, V., Mastrangelo, M., Battini, R., & Cioni, G. (2013). Inborn errors of creatine metabolism and epilepsy. Epilepsia, 54(2), 217-227.
Ferretti, A., Battini, R., Gagliardo, O., Verrigni, D., Manca, M. B., Ferrari, A. R., Salerno, G., Boccia, R., Polese, D., Cocco, C., Zampogna, S., Di Nardo, G., Evangelisti, M., Pagani, J., Bruni, O., Romano, A., Piastra, M., Simmaco, M., Rocco, M., … Parisi, P. (2025). Epilepsy expands the phenotype of L-arginine:glycine amidinotransferase deficiency. Epilepsia, 66(11), 4425-4433.
Fortunato, F., De Fiores, R., Sammarra, I., Bonacci, M. C., Caligiuri, M. E., Sturniolo, M., Martino, I., & Gambardella, A. (2025). Focal epilepsy with sensory seizures associated with arginine:glycine amidinotransferase deficiency: A clinical and advanced magnetic resonance imaging study. Epilepsia, 66(7).
Reichold, M., Klootwijk, E. D., Reinders, J., Otto, E. A., Milani, M., Broeker, C., Laing, C., Wiesner, J., Devi, S., Zhou, W., Schmitt, R., Tegtmeier, I., Sterner, C., Doellerer, H., Renner, K., Oefner, P. J., Dettmer, K., Simbuerger, J. M., Witzgall, R., … Kleta, R. (2018). Glycine amidinotransferase (GATM), renal Fanconi syndrome, and kidney failure. Journal of the American Society of Nephrology, 29(7), 1849-1858.
Carducci, C., Birarelli, M., Leuzzi, V., Carducci, C., Battini, R., Cioni, G., & Antonozzi, I. (2002). Guanidinoacetate and creatine plus creatinine assessment in physiologic fluids: An effective diagnostic tool for the biochemical diagnosis of Arginine:Glycine amidinotransferase and guanidinoacetate methyltransferase deficiencies. Clinical Chemistry, 48(10), 1772-1778.
Almeida, L. S., Verhoeven, N. M., Roos, B., Valongo, C., Cardoso, M. L., Vilarinho, L., Salomons, G. S., & Jakobs, C. (2004). Creatine and guanidinoacetate: Diagnostic markers for inborn errors in creatine biosynthesis and transport. Molecular Genetics and Metabolism, 82(3), 214-219.
Sakaguchi, S. (1925). Über eine neue Farbenreaktion von Protein und Arginin. The Journal of Biochemistry, 5(1), 25-31.
Schulze, A., Hess, T., Wevers, R., Mayatepek, E., Bachert, P., Marescau, B., Knopp, M. V., De Deyn, P. P., Bremer, H. J., & Rating, D. (1997). Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: Diagnostic tools for a new inborn error of metabolism. The Journal of Pediatrics, 131(4), 626-631.
Stöckler, S., Marescau, B., De Deyn, P. R., Trijbels, J. M. F., & Hanefeld, F. (1997). Guanidino compounds in guanidinoacetate methyltransferase deficiency, a new inborn error of creatine synthesis. Metabolism, 46(10), 1189-1193.
Struys, E. A., Jansen, E. E. W., ten Brink, H. J., Verhoeven, N. M., van der Knaap, M. S., & Jakobs, C. (1998). An accurate stable isotope dilution gas chromatographic–mass spectrometric approach to the diagnosis of guanidinoacetate methyltransferase deficiency. Journal of Pharmaceutical and Biomedical Analysis, 18(4-5), 659-665.
Bodamer, O. A., Bloesch, S. M., Gregg, A. R., Stockler-Ipsiroglu, S., & O'Brien, W. E. (2001). Analysis of guanidinoacetate and creatine by isotope dilution electrospray tandem mass spectrometry. Clinica Chimica Acta, 308(1-2), 173-178.
Carducci, C., Birarelli, M., Santagata, P., Leuzzi, V., Carducci, C., & Antonozzi, I. (2001). Automated high-performance liquid chromatographic method for the determination of guanidinoacetic acid in dried blood spots: A tool for early diagnosis of guanidinoacetate methyltransferase deficiency. Journal of Chromatography B: Biomedical Sciences and Applications, 755(1-2), 343-348.
Carducci, C., Santagata, S., Leuzzi, V., Carducci, C., Artiola, C., Giovanniello, T., Battini, R., & Antonozzi, I. (2006). Quantitative determination of guanidinoacetate and creatine in dried blood spot by flow injection analysis-electrospray tandem mass spectrometry. Clinica Chimica Acta, 364(1-2), 180-187.
Ilas, J., Mühl, A., & Stöckler-Ipsiroglu, S. (2000). Guanidinoacetate methyltransferase (GAMT) deficiency: Non-invasive enzymatic diagnosis of a newly recognized inborn error of metabolism. Clinica Chimica Acta, 290(2), 179-188.
Verhoeven, N. M., Schor, D. S. M., Roos, B., Battini, R., Stöckler-Ipsiroglu, S., Salomons, G. S., & Jakobs, C. (2003). Diagnostic enzyme assay that uses stable-isotope-labeled substrates to detect L-arginine:glycine amidinotransferase deficiency. Clinical Chemistry, 49(5), 803-805.
Verhoeven, N. M., Roos, B., Struys, E. A., Salomons, G. S., van der Knaap, M. S., & Jakobs, C. (2004). Enzyme assay for diagnosis of guanidinoacetate methyltransferase deficiency. Clinical Chemistry, 50(2), 441-443.
Arias, A., Corbella, M., Fons, C., Sempere, A., García-Villoria, J., Ormazabal, A., Poo, P., Pineda, M., Vilaseca, M. A., Campistol, J., Briones, P., Pàmpols, T., Salomons, G. S., Ribes, A., & Artuch, R. (2007). Creatine transporter deficiency: Prevalence among patients with mental retardation and pitfalls in metabolite screening. Clinical Biochemistry, 40(16-17), 1328-1331.
Comeaux, M. S., Wang, J., Wang, G., Kleppe, S., Zhang, V. W., Schmitt, E. S., Craigen, W. J., Renaud, D., Sun, Q., & Wong, L.-J. (2013). Biochemical, molecular, and clinical diagnoses of patients with cerebral creatine deficiency syndromes. Molecular Genetics and Metabolism, 109(3), 260-268.
Sanders, K., Peck, D., Bentz Pino, G., Studinski Jones, A., White, A., Gavrilov, D., Matern, D., Oglesbee, D., Schultz, M., Tortorelli, S., & Hall, P. L. (2024). SLC6A8 creatine transporter deficiency can be detected by plasma creatine and creatinine concentrations. Molecular Genetics and Metabolism, 142(1), 108455.
Sharer, J. D., Bodamer, O., Longo, N., Tortorelli, S., Wamelink, M. M. C., & Young, S. (2017). Laboratory diagnosis of creatine deficiency syndromes: A technical standard and guideline of the American College of Medical Genetics and Genomics. Genetics in Medicine, 19(2), 256-263.
Rosenberg, E. H., Almeida, L. S., Kleefstra, T., deGrauw, R. S., Yntema, H. G., Bahi, N., Moraine, C., Ropers, H.-H., Fryns, J.-P., deGrauw, T. J., Jakobs, C., & Salomons, G. S. (2004). High prevalence of SLC6A8 deficiency in X-linked mental retardation. The American Journal of Human Genetics, 75(1), 97-105.
Clark, A. J., Rosenberg, E. H., Almeida, L. S., Wood, T. C., Jakobs, C., Stevenson, R. E., Schwartz, C. E., & Salomons, G. S. (2006). X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology. Human Genetics, 119(6), 604-610.
Cheillan, D., Curt, M. J.-C., Briand, G., Salomons, G. S., Mention-Mulliez, K., Dobbelaere, D., Cuisset, J.-M., Lion-François, L., Portes, V. D., Chabli, A., Valayannopoulos, V., Benoist, J.-F., Pinard, J.-M., Simard, G., Douay, O., Deiva, K., Afenjar, A., Héron, D., Rivier, F., … Vamecq, J. (2012). Screening for primary creatine deficiencies in French patients with unexplained neurological symptoms. Orphanet Journal of Rare Diseases, 7(1).
Schulze, A., Bauman, M., Tsai, A. C.-H., Reynolds, A., Roberts, W., Anagnostou, E., Cameron, J., Nozzolillo, A. A., Chen, S., Kyriakopoulou, L., Scherer, S. W., & Loh, A. (2016). Prevalence of creatine deficiency syndromes in children with nonsyndromic autism. Pediatrics, 137(1).
Shevell, M., Ashwal, S., Donley, D., Flint, J., Gingold, M., Hirtz, D., Majnemer, A., Noetzel, M., & Sheth, R. D. (2003). Practice parameter: Evaluation of the child with global developmental delay [RETIRED]: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 60(3), 367-380.
Michelson, D. J., Shevell, M. I., Sherr, E. H., Moeschler, J. B., Gropman, A. L., & Ashwal, S. (2011). Evidence report: Genetic and metabolic testing on children with global developmental delay [RETIRED]: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 77(17), 1629-1635.
Schulze, A., Hoffmann, G. F., Bachert, P., Kirsch, S., Salomons, G. S., Verhoeven, N. M., & Mayatepek, E. (2006). Presymptomatic treatment of neonatal guanidinoacetate methyltransferase deficiency. Neurology, 67(4), 719-721.
El-Gharbawy, A. H., Goldstein, J. L., Millington, D. S., Vaisnins, A. E., Schlune, A., Barshop, B. A., Schulze, A., Koeberl, D. D., & Young, S. P. (2013). Elevation of guanidinoacetate in newborn dried blood spots and impact of early treatment in GAMT deficiency. Molecular Genetics and Metabolism, 109(2), 215-217.
Mercimek-Mahmutoglu, S., Sinclair, G., van Dooren, S. J. M., Kanhai, W., Ashcraft, P., Michel, O. J., Nelson, J., Betsalel, O. T., Sweetman, L., Jakobs, C., & Salomons, G. S. (2012). Guanidinoacetate methyltransferase deficiency: First steps to newborn screening for a treatable neurometabolic disease. Molecular Genetics and Metabolism, 107(3), 433-437.
Pasquali, M., Schwarz, E., Jensen, M., Yuzyuk, T., DeBiase, I., Randall, H., & Longo, N. (2014). Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiency. Journal of Inherited Metabolic Disease, 37(2), 231-236.
Sinclair, G. B., van Karnebeek, C. D. M., Ester, M., Boyd, F., Nelson, T., Stockler-Ipsiroglu, S., & Vallance, H. (2016). A three-tier algorithm for guanidinoacetate methyltransferase (GAMT) deficiency newborn screening. Molecular Genetics and Metabolism, 118(3), 173-177.
Hart, K., Rohrwasser, A., Wallis, H., Golsan, H., Shao, J., Anderson, T., Wang, X., Szabo-Fresnais, N., Morrissey, M., Kay, D. M., Wojcik, M., Galvin-Parton, P. A., Longo, N., Caggana, M., & Pasquali, M. (2021). Prospective identification by neonatal screening of patients with guanidinoacetate methyltransferase deficiency. Molecular Genetics and Metabolism, 134(1-2), 60-64.
Wojcik, M., Morrissey, M., Borden, K., Teta, B., Sicko, R., Showers, A., Sunny, S., & Caggana, M. (2022). Method modification to reduce false positives for newborn screening of guanidinoacetate methyltransferase deficiency. Molecular Genetics and Metabolism, 135(3), 186-192.
Verhoeven, N. M., Salomons, G. S., & Jakobs, C. (2005). Laboratory diagnosis of defects of creatine biosynthesis and transport. Clinica Chimica Acta, 361(1-2), 1-9.
Clark, J. F., & Cecil, K. M. (2015). Diagnostic methods and recommendations for the cerebral creatine deficiency syndromes. Pediatric Research, 77(3), 398-405.
Rackayova, V., Cudalbu, C., Pouwels, P. J. W., & Braissant, O. (2017). Creatine in the central nervous system: From magnetic resonance spectroscopy to creatine deficiencies. Analytical Biochemistry, 529, 144-157.
Sijens, P. E., Verbruggen, K. T., Meiners, L. C., Soorani-Lunsing, R. J., Rake, J. P., & Oudkerk, M. (2005). 1H chemical shift imaging of the brain in guanidino methyltransferase deficiency, a creatine deficiency syndrome; Guanidinoacetate accumulation in the gray matter. European Radiology, 15(9), 1923-1926.
Dezortova, M., Jiru, F., Petrasek, J., Malinova, V., Zeman, J., Jirsa, M., & Hajek, M. (2008). 1H MR spectroscopy as a diagnostic tool for cerebral creatine deficiency. Magnetic Resonance Materials in Physics, Biology and Medicine, 21(5), 327-332.
Schulze, A., Bachert, P., Schlemmer, H., Harting, I., Polster, T., Salomons, G. S., Verhoeven, N. M., Jakobs, C., Fowler, B., Hoffmann, G. F., & Mayatepek, E. (2003). Lack of creatine in muscle and brain in an adult with GAMT deficiency. Annals of Neurology, 53(2), 248-251.
Ensenauer, R., Thiel, T., Schwab, K. O., Tacke, U., Stöckler-Ipsiroglu, S., Schulze, A., Hennig, J., & Lehnert, W. (2004). Guanidinoacetate methyltransferase deficiency: Differences of creatine uptake in human brain and muscle. Molecular Genetics and Metabolism, 82(3), 208-213.
Dreha-Kulaczewski, S., Kalscheuer, V., Tzschach, A., Hu, H., Helms, G., Brockmann, K., Weddige, A., Dechent, P., Schlüter, G., Krätzner, R., Ropers, H. H., Gärtner, J., & Zirn, B. (2013). A novel SLC6A8 mutation in a large family with X-linked intellectual disability: Clinical and proton magnetic resonance spectroscopy data of both hemizygous males and heterozygous females. In JIMD Reports - Case and Research Reports, Volume 13 (pp. 91-99). Springer Berlin Heidelberg.
Verbruggen, K. T., Meiners, L. C., Sijens, P. E., Lunsing, R. J., van Spronsen, F. J., & Brouwer, O. F. (2009). Magnetic resonance imaging and proton magnetic resonance spectroscopy of the brain in the diagnostic evaluation of developmental delay. European Journal of Paediatric Neurology, 13(2), 181-190.
Newmeyer, A., Cecil, K. M., Schapiro, M., Clark, J. F., & Degrauw, T. J. (2005). Incidence of brain creatine transporter deficiency in males with developmental delay referred for brain magnetic resonance imaging. Journal of Developmental & Behavioral Pediatrics, 26(4), 276-282.
Bianchi, M. C., Tosetti, M., Battini, R., Leuzzi, V., Alessandri', M. G., Carducci, C., Antonozzi, I., & Cioni, G. (2007). Treatment monitoring of brain creatine deficiency syndromes: A 1H- and 31P-MR spectroscopy study. American Journal of Neuroradiology, 28(3), 548–554.
Marten, L. M., Krätzner, R., Salomons, G. S., Fernandez Ojeda, M., Dechent, P., Gärtner, J., Huppke, P., & Dreha-Kulaczewski, S. (2024). Long term follow-up in GAMT deficiency – correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data. Molecular Genetics and Metabolism Reports, 38, 101053.
van de Kamp, J. M., Pouwels, P. J. W., Aarsen, F. K., ten Hoopen, L. W., Knol, D. L., de Klerk, J. B., de Coo, I. F., Huijmans, J. G. M., Jakobs, C., van der Knaap, M. S., Salomons, G. S., & Mancini, G. M. S. (2012). Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect. Journal of Inherited Metabolic Disease, 35(1), 141-149.
Valayannopoulos, V., Boddaert, N., Chabli, A., Barbier, V., Desguerre, I., Philippe, A., Afenjar, A., Mazzuca, M., Cheillan, D., Munnich, A., de Keyzer, Y., Jakobs, C., Salomons, G. S., & de Lonlay, P. (2012). Treatment by oral creatine, L-arginine and L-glycine in six severely affected patients with creatine transporter defect. Journal of Inherited Metabolic Disease, 35(1), 151-157.
Nasseri Moghaddam, Z., Reinhardt, E. K., Thurm, A., Potter, B. K., Smith, M., Graham, C., Tiller, B. H., Baker, S. A., Bilder, D. A., Bogar, R., Britz, J., Cafferty, R., Coller, D. P., DeGrauw, T. J., Hall, V., Lipshutz, G. S., Longo, N., Mercimek-Andrews, S., Miller, J. S., … Wallis, H. (2025). Establishing a core outcome set for creatine transporter deficiency and guanidinoacetate methyltransferase deficiency. Orphanet Journal of Rare Diseases, 20(1).
Cecil, K. M., Henry, P. G., Wallis, H., Thurm, A., & Roberts, T. P. L. (2026). A call for pediatric magnetic resonance spectroscopy harmonization in neurometabolic disorders with a simple approach for diagnosis, treatment monitoring and data aggregation for clinical trials. American Journal of Neuroradiology.
Haris, M., Nanga, R. P. R., Singh, A., Cai, K., Kogan, F., Hariharan, H., & Reddy, R. (2012). Exchange rates of creatine kinase metabolites: Feasibility of imaging creatine by chemical exchange saturation transfer MRI. NMR in Biomedicine, 25(11), 1305-1309.
Kogan, F., Haris, M., Debrosse, C., Singh, A., Nanga, R. P., Cai, K., Hariharan, H., & Reddy, R. (2014). In vivo chemical exchange saturation transfer imaging of creatine (CrCEST) in skeletal muscle at 3T: Muscle CrCEST at 3T. Journal of Magnetic Resonance Imaging, 40(3), 596-602.
Chen, L., Zeng, H., Xu, X., Yadav, N. N., Cai, S., Puts, N. A., Barker, P. B., Li, T., Weiss, R. G., van Zijl, P. C. M., & Xu, J. (2017). Investigation of the contribution of total creatine to the CEST Z-spectrum of brain using a knockout mouse model. NMR in Biomedicine, 30(12).
Wang, K., Huang, J., Ju, L., Xu, S., Gullapalli, R. P., Liang, Y., Rogers, J., Li, Y., van Zijl, P. C. M., Weiss, R. G., Chan, K. W. Y., & Xu, J. (2024). Creatine mapping of the brain at 3T by CEST MRI. Magnetic Resonance in Medicine, 91(1), 51-60.
Singh, A., Debnath, A., Cai, K., Bagga, P., Haris, M., Hariharan, H., & Reddy, R. (2019). Evaluating the feasibility of creatine-weighted CEST MRI in human brain at 7 T using a Z-spectral fitting approach. NMR in Biomedicine, 32(12).
Wang, Z., Zhang, H., Wang, J., Zhang, Y., & Huang, J. (2026). Comparing multi-pool Lorentzian fitting methods for guanidinium CEST quantification in the human brain at clinical 3 T : A validation study using MRS. Magnetic Resonance in Medicine.
Ohtsuki, S., Tachikawa, M., Takanaga, H., Shimizu, H., Watanabe, M., Hosoya, K.-I., & Terasaki, T. (2002). The blood–brain barrier creatine transporter is a major pathway for supplying creatine to the brain. Journal of Cerebral Blood Flow & Metabolism, 22(11), 1327-1335.
Perasso, L., Cupello, A., Lunardi, G. L., Principato, C., Gandolfo, C., & Balestrino, M. (2003). Kinetics of creatine in blood and brain after intraperitoneal injection in the rat. Brain Research, 974(1-2), 37-42.
Braissant, O., Henry, H., Loup, M., Eilers, B., & Bachmann, C. (2001). Endogenous synthesis and transport of creatine in the rat brain: An in situ hybridization study. Molecular Brain Research, 86(1-2), 193-201.
Braissant, O., & Henry, H. (2008). AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: A review. Journal of Inherited Metabolic Disease, 31(2), 230-239.
Braissant, O., Béard, E., Torrent, C., & Henry, H. (2010). Dissociation of AGAT, GAMT and SLC6A8 in CNS: Relevance to creatine deficiency syndromes. Neurobiology of Disease, 37(2), 423-433.
Braissant, O. (2012). Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers. Journal of Inherited Metabolic Disease, 35(4), 655-664.
Jinnai, D., Sawai, A., & Mori, A. (1966). γ-Guanidinobutyric acid as a convulsive substance. Nature, 212(5062), 617-617.
De Deyn, P. P., & Macdonald, R. L. (1990). Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture. Annals of Neurology, 28(5), 627-633.
Neu, A., Neuhoff, H., Trube, G., Fehr, S., Ullrich, K., Roeper, J., & Isbrandt, D. (2002). Activation of GABAA receptors by guanidinoacetate: A novel pathophysiological mechanism. Neurobiology of Disease, 11(2), 298-307.
Meera, P., Uusi-Oukari, M., Wallner, M., & Lipshutz, G. S. (2023). Guanidinoacetate (GAA) is a potent GABAA receptor GABA mimetic: Implications for neurological disease pathology. Journal of Neurochemistry, 165(3), 445-454.
Cupello, A., Balestrino, M., Gatta, E., Pellistri, F., Siano, S., & Robello, M. (2008). Activation of cerebellar granule cells GABAA receptors by guanidinoacetate. Neuroscience, 152(1), 65-69.
Poggio, F., Brofiga, M., Tedesco, M., Massobrio, P., Adriano, E., & Balestrino, M. (2022). Lack of epileptogenic effects of the creatine precursor guanidinoacetic acid on neuronal cultures in vitro. Biomolecules, 13(1), 74.
Adriano, E., Salis, A., Damonte, G., Millo, E., & Balestrino, M. (2022). Effects of delivering guanidinoacetic acid or its prodrug to the neural tissue: Possible relevance for creatine transporter deficiency. Brain Sciences, 12(1), 85.
Schulze, A., Tran, C., Levandovskiy, V., Patel, V., & Cortez, M. A. (2016). Systemic availability of guanidinoacetate affects GABAA receptor function and seizure threshold in GAMT deficient mice. Amino Acids, 48(8), 2041-2047.
Renema, W. K. J., Schmidt, A., van Asten, J. J. A., Oerlemans, F., Ullrich, K., Wieringa, B., Isbrandt, D., & Heerschap, A. (2003). MR spectroscopy of muscle and brain in guanidinoacetate methyltransferase (GAMT)-deficient mice: Validation of an animal model to study creatine deficiency. Magnetic Resonance in Medicine, 50(5), 936-943.
Schmidt, A. (2004). Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. Human Molecular Genetics, 13(9), 905-921.
Skelton, M. R., Schaefer, T. L., Graham, D. L., deGrauw, T. J., Clark, J. F., Williams, M. T., & Vorhees, C. V. (2011). Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. PLoS ONE, 6(1), e16187.
Baroncelli, L., Alessandrì, M. G., Tola, J., Putignano, E., Migliore, M., Amendola, E., Gross, C., Leuzzi, V., Cioni, G., & Pizzorusso, T. (2014). A novel mouse model of creatine transporter deficiency. F1000Research, 3, 228.
Kurosawa, Y., DeGrauw, T. J., Lindquist, D. M., Blanco, V. M., Pyne-Geithman, G. J., Daikoku, T., Chambers, J. B., Benoit, S. C., & Clark, J. F. (2012). Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency. Journal of Clinical Investigation, 122(8), 2837-2846.
Udobi, K. C., Kokenge, A. N., Hautman, E. R., Ullio, G., Coene, J., Williams, M. T., Vorhees, C. V., Mabondzo, A., & Skelton, M. R. (2018). Cognitive deficits and increases in creatine precursors in a brain-specific knockout of the creatine transporter gene Slc6a8. Genes, Brain and Behavior, 17(6).
Molinaro, A., Alessandrì, M. G., Putignano, E., Leuzzi, V., Cioni, G., Baroncelli, L., & Pizzorusso, T. (2019). A nervous system-specific model of creatine transporter deficiency recapitulates the cognitive endophenotype of the disease: A longitudinal study. Scientific Reports, 9(1).
Udobi, K. C., Delcimmuto, N., Kokenge, A. N., Abdulla, Z. I., Perna, M. K., & Skelton, M. R. (2019). Deletion of the creatine transporter gene in neonatal, but not adult, mice leads to cognitive deficits. Journal of Inherited Metabolic Disease, 42(5), 966-974.
Duran-Trio, L., Fernandes-Pires, G., Simicic, D., Grosse, J., Roux-Petronelli, C., Bruce, S. J., Binz, P.-A., Sandi, C., Cudalbu, C., & Braissant, O. (2021). A new rat model of creatine transporter deficiency reveals behavioral disorder and altered brain metabolism. Scientific Reports, 11(1).
Mazziotti, R., Cacciante, F., Sagona, G., Lupori, L., Gennaro, M., Putignano, E., Alessandrì, M. G., Ferrari, A., Battini, R., Cioni, G., Pizzorusso, T., & Baroncelli, L. (2020). Novel translational phenotypes and biomarkers for creatine transporter deficiency. Brain Communications, 2(2).
Ghirardini, E., Sagona, G., Marquez-Galera, A., Calugi, F., Navarron, C. M., Cacciante, F., Chen, S., Di Vetta, F., Dadà, L., Mazziotti, R., Lupori, L., Putignano, E., Baldi, P., Lopez-Atalaya, J. P., Pizzorusso, T., & Baroncelli, L. (2023). Cell-specific vulnerability to metabolic failure: The crucial role of parvalbumin expressing neurons in creatine transporter deficiency. Acta Neuropathologica Communications, 11(1).
Broca-Brisson, L., Harati, R., Disdier, C., Mozner, O., Gaston-Breton, R., Maïza, A., Costa, N., Guyot, A.-C., Sarkadi, B., Apati, A., Skelton, M. R., Madrange, L., Yates, F., Armengaud, J., Hamoudi, R., & Mabondzo, A. (2023). Deciphering neuronal deficit and protein profile changes in human brain organoids from patients with creatine transporter deficiency. eLife, 12.
Lygate, C. A., Aksentijevic, D., Dawson, D., ten Hove, M., Phillips, D., de Bono, J. P., Medway, D. J., Sebag-Montefiore, L., Hunyor, I., Channon, K. M., Clarke, K., Zervou, S., Watkins, H., Balaban, R. S., & Neubauer, S. (2013). Living without creatine: Unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. Circulation Research, 112(6), 945-955.
Nabuurs, C. I., Choe, C. U., Veltien, A., Kan, H. E., van Loon, L. J. C., Rodenburg, R. J. T., Matschke, J., Wieringa, B., Kemp, G. J., Isbrandt, D., & Heerschap, A. (2013). Disturbed energy metabolism and muscular dystrophy caused by pure creatine deficiency are reversible by creatine intake. The Journal of Physiology, 591(2), 571-592.
Li, S., Bianconi, S., van der Veen, J. W., Dang Do, A., Stolinski, J., Cecil, K. M., Hannah-Shmouni, F., Porter, F. D., & Shen, J. (2021). Oxidative phosphorylation in creatine transporter deficiency. NMR in Biomedicine, 34(1).
Schulze, A., Mayatepek, E., Bachert, P., Marescau, B., De Deyn, P. P., & Rating, D. (1998). Therapeutic trial of arginine restriction in creatine deficiency syndrome. European Journal of Pediatrics, 157(7), 606-607.
Sipilä, I. (1980). Inhibition of arginine-glycine amidinotransferase by ornithine. A possible mechanism for the muscular and chorioretinal atrophies in gyrate atrophy of the choroid and retina with hyperornithinemia. Biochimica et Biophysica Acta (BBA) - Enzymology, 613(1), 79-84.
Schulze, A., Ebinger, F., Rating, D., & Mayatepek, E. (2001). Improving treatment of guanidinoacetate methyltransferase deficiency: Reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation. Molecular Genetics and Metabolism, 74(4), 413-419.
Viau, K. S., Ernst, S. L., Pasquali, M., Botto, L. D., Hedlund, G., & Longo, N. (2013). Evidence-based treatment of guanidinoacetate methyltransferase (GAMT) deficiency. Molecular Genetics and Metabolism, 110(3), 255-262.
Mercimek-Mahmutoglu, S., Dunbar, M., Friesen, A., Garret, S., Hartnett, C., Huh, L., Sinclair, G., Stockler, S., Wellington, S., Pouwels, P. J. W., Salomons, G. S., & Jakobs, C. (2012). Evaluation of two year treatment outcome and limited impact of arginine restriction in a patient with GAMT deficiency. Molecular Genetics and Metabolism, 105(1), 155-158.
Tkachyova, I., Wang, D., Lee, A., Rößler, P., Atienza, J., Feugmann, J., Guischard, N., Hui, A., Shi, C., & Schulze, A. (2026). Creatine supplementation reduces guanidinoacetate via downregulation of AGAT in a mouse model of GAMT deficiency. Journal of Inherited Metabolic Disease, 49(5).
Battini, R., Alessandrì, M. G., Leuzzi, V., Moro, F., Tosetti, M., Bianchi, M. C., & Cioni, G. (2006). Arginine:glycine amidinotransferase (AGAT) deficiency in a newborn: Early treatment can prevent phenotypic expression of the disease. The Journal of Pediatrics, 148(6), 828-830.
Caspi, L., Hayeems, R., & Schulze, A. (2025). Outcomes in early-treated guanidinoacetate methyltransferase deficiency: A sibling cohort study. Neurology Genetics, 11(3).
Khaikin, Y., Sidky, S., Abdenur, J., Anastasi, A., Ballhausen, D., Buoni, S., Chan, A., Cheillan, D., Dorison, N., Goldenberg, A., Goldstein, J., Hofstede, F. C., Jacquemont, M.-L., Koeberl, D. D., Lion-Francois, L., Lund, A. M., Mention, K., Mundy, H., O'Rourke, D., … Mercimek-Andrews, S. (2018). Treatment outcome of twenty-two patients with guanidinoacetate methyltransferase deficiency: An international retrospective cohort study. European Journal of Paediatric Neurology, 22(3), 369-379.
Sung, W., Chen, H., Hsu, C., & Tsai, M. (2026). Reversal of refractory epilepsy in an adult with GAMT deficiency: A case report and comparative literature review. Epilepsia Open.
Khoja, S., Lambert, J., Nitzahn, M., Eliav, A., Zhang, Y., Tamboline, M., Le, C. T., Nasser, E., Li, Y., Patel, P., Zhuravka, I., Lueptow, L. M., Tkachyova, I., Xu, S., Nissim, I., Schulze, A., & Lipshutz, G. S. (2022). Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities. Molecular Therapy - Methods & Clinical Development, 25, 278-296.
Binsfeld, R., Webster, T., Tkachyova, I., Tropak, M., Mitchell, M., Peretti, T., Schulze, A., & Walia, J. S. (2026). A CNS-directed, AAV9 gene therapy restores expression and biochemical function of guanidinoacetate methyltransferase in models of GAMT deficiency. International Journal of Molecular Sciences, 27(2), 1035.
Chilosi, A., Leuzzi, V., Battini, R., Tosetti, M., Ferretti, G., Comparini, A., Casarano, M., Moretti, E., Alessandrì, M. G., Bianchi, M. C., & Cioni, G. (2008). Treatment with L-arginine improves neuropsychological disorders in a child with creatine transporter defect. Neurocase, 14(2), 151-161.
Fons, C., Sempere, A., Arias, A., López-Sala, A., Póo, P., Pineda, M., Mas, A., Vilaseca, M. A., Salomons, G. S., Ribes, A., Artuch, R., & Campistol, J. (2008). Arginine supplementation in four patients with X-linked creatine transporter defect. Journal of Inherited Metabolic Disease, 31(6), 724-728.
Dunbar, M., Jaggumantri, S., Sargent, M., Stockler-Ipsiroglu, S., & van Karnebeek, C. D. M. (2014). Treatment of X-linked creatine transporter (SLC6A8) deficiency: Systematic review of the literature and three new cases. Molecular Genetics and Metabolism, 112(4), 259-274.
Bruun, T. U. J., Sidky, S., Bandeira, A. O., Debray, F.-G., Ficicioglu, C., Goldstein, J., Joost, K., Koeberl, D. D., Luísa, D., Nassogne, M.-C., O’Sullivan, S., Õunap, K., Schulze, A., van Maldergem, L., Salomons, G. S., & Mercimek-Andrews, S. (2018). Treatment outcome of creatine transporter deficiency: International retrospective cohort study. Metabolic Brain Disease, 33(3), 875-884.
Mercimek-Mahmutoglu, S., Connolly, M. B., Poskitt, K. J., Horvath, G. A., Lowry, N., Salomons, G. S., Casey, B., Sinclair, G., Davis, C., Jakobs, C., & Stockler-Ipsiroglu, S. (2010). Treatment of intractable epilepsy in a female with SLC6A8 deficiency. Molecular Genetics and Metabolism, 101(4), 409-412.
Tauer, K., Theile, C., Owens, J. W., Cecil, K. M., & Shillington, A. (2024). Arginine, glycine, and creatine supplementation improves symptoms in a female with creatine transporter deficiency. Psychiatric Genetics, 34(4), 86-90.
Longo, N., Voss, L. A., Frigeni, M., Balakrishnan, B., & Pasquali, M. (2024). Response to therapy of creatine transporter deficiency caused by a hypomorphic variant in SLC6A8. Molecular Genetics and Metabolism, 143(3), 108595.
Villar, C., Campistol, J., Fons, C., Armstrong, J., Mas, A., Ormazabal, A., & Artuch, R. (2011). Glycine and L-arginine treatment causes hyperhomocysteinemia in cerebral creatine transporter deficiency patients. In JIMD Reports - Case and Research Reports, 2012/1 (pp. 13-16). Springer Berlin Heidelberg.
Fons, C., Arias, A., Sempere, A., Póo, P., Pineda, M., Mas, A., López-Sala, A., Garcia-Villoria, J., Vilaseca, M. A., Ozaez, L., Lluch, M., Artuch, R., Campistol, J., & Ribes, A. (2010). Response to creatine analogs in fibroblasts and patients with creatine transporter deficiency. Molecular Genetics and Metabolism, 99(3), 296-299.
Adriano, E., Garbati, P., Damonte, G., Salis, A., Armirotti, A., & Balestrino, M. (2011). Searching for a therapy of creatine transporter deficiency: Some effects of creatine ethyl ester in brain slices in vitro. Neuroscience, 199, 386-393.
Cacciante, F., Gennaro, M., Sagona, G., Mazziotti, R., Lupori, L., Cerri, E., Putignano, E., Butt, M., Do, M.-H. T., McKew, J. C., Alessandrì, M. G., Battini, R., Cioni, G., Pizzorusso, T., & Baroncelli, L. (2020). Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter deficiency. Scientific Reports, 10(1).
Kale, V. P., Wallery, J., Novak, J., Gibbs, S., Bourdi, M., Do, M.-H. T., McKew, J. C., & Terse, P. S. (2020). Evaluation of chronic toxicity of cyclocreatine, a creatine analog, in Sprague Dawley rat after oral gavage administration for up to 26 weeks. Regulatory Toxicology and Pharmacology, 117, 104750.
Wallery, J. J., Kale, V. P., Novak, J., Gibbs, S., Do, M.-H. T., McKew, J. C., & Terse, P. S. (2021). Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks. Toxicology and Applied Pharmacology, 430, 115680.
Uemura, T., Ito, S., Masuda, T., Shimbo, H., Goto, T., Osaka, H., Wada, T., Couraud, P.-O., & Ohtsuki, S. (2020). Cyclocreatine transport by SLC6A8, the creatine transporter, in HEK293 cells, a human blood-brain barrier model cell, and CCDSs patient-derived fibroblasts. Pharmaceutical Research, 37(3).
Trotier-Faurion, A., Dézard, S., Taran, F., Valayannopoulos, V., de Lonlay, P., & Mabondzo, A. (2013). Synthesis and biological evaluation of New creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency. Journal of Medicinal Chemistry, 56(12), 5173-5181.
Trotier-Faurion, A., Passirani, C., Béjaud, J., Dézard, S., Valayannopoulos, V., Taran, F., de Lonlay, P., Benoit, J.-P., & Mabondzo, A. (2015). Dodecyl creatine ester and lipid nanocapsule: A double strategy for the treatment of creatine transporter deficiency. Nanomedicine, 10(2), 185-191.
Ullio-Gamboa, G., Udobi, K. C., Dezard, S., Perna, M. K., Miles, K. N., Costa, N., Taran, F., Pruvost, A., Benoit, J.-P., Skelton, M. R., Lonlay, P. D., & Mabondzo, A. (2019). Dodecyl creatine ester-loaded nanoemulsion as a promising therapy for creatine transporter deficiency. Nanomedicine, 14(12), 1579-1593.
Disdier, C., Lhotellier, C., Guyot, A.-C., Costa, N., Théodoro, F., Pruvost, A., Skelton, M. R., Joudinaud, T., Mabondzo, A., & Bénech, H. (2025). Dodecyl creatine ester, a promising treatment to deliver creatine to neurons, achieves pharmacology efficacy in creatine transporter deficiency. European Journal of Medicinal Chemistry, 284, 117195.
Mabondzo, A., Harati, R., Broca-Brisson, L., Guyot, A.-C., Costa, N., Cacciante, F., Putignano, E., Baroncelli, L., Skelton, M. R., Saab, C., Martini, E., Benech, H., Joudinaud, T., Gaillard, J.-C., Armengaud, J., & Hamoudi, R. (2023). Dodecyl creatine ester improves cognitive function and identifies key protein drivers including KIF1A and PLCB1 in a mouse model of creatine transporter deficiency. Frontiers in Molecular Neuroscience, 16.
Disdier, C., Soyer, A., Broca-Brisson, L., Goutal, S., Guyot, A.-C., Ziani, N., Breuil, L., Winkeler, A., Hugon, G., Joudinaud, T., Bénech, H., Armengaud, J., Skelton, M. R., Harati, R., Hamoudi, R. A., Tournier, N., & Mabondzo, A. (2024). Impaired brain glucose metabolism as a biomarker for evaluation of dodecyl creatine ester in creatine transporter deficiency: Insights from patient brain-derived organoids and in vivo [18F]FDG PET imaging in a mouse model. Neurobiology of Disease, 202, 106720.
Broca-Brisson, L., Disdier, C., Harati, R., Hamoudi, R., & Mabondzo, A. (2024). Epigenetic alterations in creatine transporter deficiency: A new marker for dodecyl creatine ester therapeutic efficacy monitoring. Frontiers in Neuroscience, 18.
Gechijian, L. N., Muncipinto, G., Rettenmaier, T. J., Labenski, M. T., Rusu, V., Rosskamp, L., Conway, L., van Kalken, D., Gross, L., Iantosca, G., Crotty, W., Mathis, R., Park, H., Rabin, B., Westgate, C., Lyons, M., Deshusses, C., Brandon, N., Brown, D. G., … Barrish, J. C. (2024). Novel corrector for variants of SLC6A8: A therapeutic opportunity for creatine transporter deficiency. ACS Chemical Biology, 19(11), 2372-2382.
Fernandes-Pires, G., Azevedo, M. D., Lanzillo, M., Roux-Petronelli, C., Binz, P.-A., Cudalbu, C., Sandi, C., Tenenbaum, L., & Braissant, O. (2024). Rescue of myocytes and locomotion through AAV2/9-2YF intracisternal gene therapy in a rat model of creatine transporter deficiency. Molecular Therapy - Methods & Clinical Development, 32(2), 101251.
Montani, C., Iovino, L., Di Vetta, F., Pasquin Mariani, J.-C. R., De Guzman, A. E., Gini, S., Galbusera, A., D’Epifanio, B., Ghirardini, E., Cornuti, S., Dadà, L., Putignano, E., Alessandrì, M. G., Vasirani, G., Bertozzi, S. M., Armirotti, A., Baroncelli, L., & Gozzi, A. (2026). Connectomic and behavioural alterations in creatine transporter deficiency are partially normalized by gene therapy. Brain, 149(3), 1043-1057.
Wells, C., Sorgenfrei, J., Johnson, S. L., Albertson, D., Rutter, J., & Baker, S. A. (2025). Gene delivery of AGAT and GAMT boosts creatine levels in creatine transporter deficiency patient fibroblasts. PLOS One, 20(5), e0319350.
Wallis, H., Iyer, S., & Reinhardt, E. K. (2025). How a patient-led advocacy organization supports the road to diagnosis and treatment of creatine transporter deficiency. Frontiers in Neuroscience, 19.
Fernandes-Pires, G., & Braissant, O. (2022). Current and potential new treatment strategies for creatine deficiency syndromes. Molecular Genetics and Metabolism, 135(1), 15-26.